Skip to content
Open access · OA via OpenAlex

mTOR regulates tau phosphorylation and degradation: implications for Alzheimer's disease and other tauopathies

Antonella Caccamo, Andrea Magrì, David X. Medina, Elena V. Wisely, Manuel F. López‐Aranda, Alcino J. Silva, Salvatore Oddo

Aging Cell · 2013 · ▲ 361 citations

Abstract

Accumulation of tau is a critical event in several neurodegenerative disorders, collectively known as tauopathies, which include Alzheimer's disease and frontotemporal dementia. Pathological tau is hyperphosphorylated and aggregates to form neurofibrillary tangles. The molecular mechanisms leading to tau accumulation remain unclear and more needs to be done to elucidate them. Age is a major risk factor for all tauopathies, suggesting that molecular changes contributing to the aging process may facilitate tau accumulation and represent common mechanisms across different tauopathies. Here, we use multiple animal models and complementary genetic and pharmacological approaches to show that the mammalian target of mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">rapamycin(definition) (mTOR) regulates tau phosphorylation and degradation. Specifically, we show that genetically increasing mTOR activity elevates endogenous mouse tau levels and phosphorylation. Complementary to it, we further demonstrate that pharmacologically reducing mTOR signaling with rapamycin ameliorates tau pathology and the associated behavioral deficits in a mouse model overexpressing mutant human tau. Mechanistically, we provide compelling evidence that the association between mTOR and tau is linked to GSK3β and autophagy(definition) function. In summary, we show that increasing mTOR signaling facilitates tau pathology, while reducing mTOR signaling ameliorates tau pathology. Given the overwhelming evidence that reducing mTOR signaling increases lifespan and healthspan(definition), the data presented here have profound clinical implications for aging and tauopathies and provide the molecular basis for how aging may contribute to tau pathology. Additionally, these results provide preclinical data indicating that reducing mTOR signaling may be a valid therapeutic approach for tauopathies.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1111/acel.12057
Canonical
link ↗
Fetched
2026-11-07 MST

Cite this

APA
Caccamo, A., Magrì, A., Medina, D.X., Wisely, E.V., López‐Aranda, M.F., Silva, A.J., &amp; Oddo, S. (2013). mTOR regulates tau phosphorylation and degradation: implications for Alzheimer's disease and other tauopathies. <em>Aging Cell</em>. https://doi.org/10.1111/acel.12057
Vancouver
Caccamo A, Magrì A, Medina DX, Wisely EV, López‐Aranda MF, Silva AJ, et al. mTOR regulates tau phosphorylation and degradation: implications for Alzheimer's disease and other tauopathies. Aging Cell. 2013. doi:10.1111/acel.12057.
BibTeX
@article{antonella2013mTORre, title = {mTOR regulates tau phosphorylation and degradation: implications for Alzheimer's disease and other tauopathies}, author = {Antonella Caccamo and Andrea Magrì and David X. Medina and Elena V. Wisely and Manuel F. López‐Aranda and Alcino J. Silva and Salvatore Oddo}, journal = {Aging Cell}, year = {2013}, doi = {10.1111/acel.12057}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings